Natera acquired Foresight Diagnostics for $275 million up front to integrate Foresight’s PhaseED‑seq phased‑variant enrichment technology into Natera’s Signatera circulating tumor DNA platform and to expand into hematologic minimal residual disease (MRD) testing. Natera flagged plans to use phased‑variant detection to increase ctDNA sensitivity for solid tumors and to leverage Foresight’s lymphoma MRD work to enter hematologic oncology. The deal includes earnouts tied to revenue and reimbursement milestones; Natera expects operational scale and broader clinical access for advanced MRD assays. The acquisition underscores diagnostics firms’ push to improve ctDNA sensitivity and to capture growing MRD use in trials and clinical care.